MoonLake Reports Superior Phase 3 Sonelokimab Data in HS, Confirms Q3 BLA Submission with Priority Review Intent
MLTX has more than doubled off its 52-week low of $5.95.
Summary
MoonLake Immunotherapeutics announced highly positive Week 52 Phase 3 clinical trial results for sonelokimab in adult and adolescent hidradenitis suppurativa, demonstrating superior efficacy and a favorable safety profile compared to competitors, reinforcing its potential as a best-in-class therapy ahead of its Q3 2026 BLA submission.
Key Events · Product Development and Regulatory · MLTX
-
Positive Phase 3 VELA Trial Results (Adult HS)
Sonelokimab (SLK) demonstrated strong and durable efficacy at Week 52 in adult patients with moderate-to-severe hidradenitis suppurativa (HS), with 67.2% achieving HiSCR75 and 33.1% achieving HiSCR100. The results are stated to be superior to competing agents.
-
Favorable Safety Profile Confirmed
SLK maintained a consistent and favorable safety profile through Week 52 in adult trials, with no new safety signals detected. A high acceptance rate (~90%) into the VELA-OLE (open-label extension) was also observed.
-
Promising Phase 3 VELA-TEEN Data (Adolescent HS)
Interim Week 24 data showed rapid onset and high response rates in adolescent HS patients, with ~68% achieving HiSCR75 and ~45% achieving HiSCR100, also with no new safety signals.
-
BLA Submission Confirmed with Priority Review Intent
MoonLake plans to submit the Biologics License Application (BLA) for SLK in HS by the end of September 2026 and intends to request Priority Review, potentially accelerating market launch.
Analysis · MLTX · Life Sciences
This filing provides the highly anticipated Week 52 clinical data for sonelokimab in Hidradenitis Suppurativa (HS), confirming its strong efficacy and safety profile in both adult and adolescent populations. The company explicitly states these results are superior to competitors, positioning sonelokimab as a potential "best-in-class" therapy. This significantly de-risks the upcoming Biologics License Application (BLA) submission and strengthens the commercial outlook for sonelokimab, which is the company's lead asset. The confirmation of a Q3 2026 BLA submission and the intent to seek Priority Review further underscore the positive momentum.
At the time of this filing, MLTX was trading at $22.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $5.95 to $62.75. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.